26.76 USD
-0.68 (-2.48%)
26.76 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to ACAD. ACAD was compared to 531 industry peers in the Biotechnology industry. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ACAD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
In the past year ACAD had a positive cash flow from operations.
In the past 5 years ACAD always reported negative net income.
In the past 5 years ACAD always reported negative operating cash flow.
1.2 Ratios
ACAD's Return On Assets of 19.63% is amongst the best of the industry. ACAD outperforms 96.80% of its industry peers.
ACAD has a better Return On Equity (28.47%) than 97.55% of its industry peers.
ACAD has a Return On Invested Capital of 7.66%. This is amongst the best in the industry. ACAD outperforms 93.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROIC | 7.66% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ACAD (24.94%) is better than 94.92% of its industry peers.
The Operating Margin of ACAD (9.02%) is better than 91.15% of its industry peers.
ACAD has a better Gross Margin (91.92%) than 93.03% of its industry peers.
In the last couple of years the Gross Margin of ACAD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ACAD is destroying value.
The number of shares outstanding for ACAD has been increased compared to 1 year ago.
Compared to 5 years ago, ACAD has more shares outstanding
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ACAD has an Altman-Z score of 6.04. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
ACAD's Altman-Z score of 6.04 is fine compared to the rest of the industry. ACAD outperforms 74.39% of its industry peers.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.04 |
ROIC/WACC0.87
WACC8.78%
2.3 Liquidity
ACAD has a Current Ratio of 3.02. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD's Current ratio of 3.02 is on the low side compared to the rest of the industry. ACAD is outperformed by 64.97% of its industry peers.
ACAD has a Quick Ratio of 2.94. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD's Quick ratio of 2.94 is on the low side compared to the rest of the industry. ACAD is outperformed by 63.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 |
3. Growth
3.1 Past
The earnings per share for ACAD have decreased strongly by -14.10% in the last year.
ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 121.75%.
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
3.2 Future
ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.78% yearly.
Based on estimates for the next years, ACAD will show a quite strong growth in Revenue. The Revenue will grow by 10.04% on average per year.
EPS Next Y73.59%
EPS Next 2Y30.49%
EPS Next 3Y32.59%
EPS Next 5Y38.78%
Revenue Next Year11.07%
Revenue Next 2Y11.24%
Revenue Next 3Y10.99%
Revenue Next 5Y10.04%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 39.94, ACAD can be considered very expensive at the moment.
Based on the Price/Earnings ratio, ACAD is valued cheaper than 91.53% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.34. ACAD is valued rather expensively when compared to this.
ACAD is valuated quite expensively with a Price/Forward Earnings ratio of 32.74.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaper than 91.90% of the companies in the same industry.
ACAD is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.56, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.94 | ||
| Fwd PE | 32.74 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 92.84% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 94.73% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.79 | ||
| EV/EBITDA | 28.5 |
4.3 Compensation for Growth
ACAD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ACAD may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 32.59% in the coming years.
PEG (NY)0.54
PEG (5Y)N/A
EPS Next 2Y30.49%
EPS Next 3Y32.59%
5. Dividend
5.1 Amount
ACAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
26.76
-0.68 (-2.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.36%
Inst Owner Change1.37%
Ins Owners0.26%
Ins Owner Change-3.63%
Market Cap4.53B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts76.92
Price Target29.85 (11.55%)
Short Float %5.64%
Short Ratio4.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)0.36%
PT rev (3m)-1.54%
EPS NQ rev (1m)10.03%
EPS NQ rev (3m)6.6%
EPS NY rev (1m)42.81%
EPS NY rev (3m)44.68%
Revenue NQ rev (1m)0.69%
Revenue NQ rev (3m)2.32%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)1.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.94 | ||
| Fwd PE | 32.74 | ||
| P/S | 4.32 | ||
| P/FCF | 20.79 | ||
| P/OCF | 14.25 | ||
| P/B | 4.94 | ||
| P/tB | 5.62 | ||
| EV/EBITDA | 28.5 |
EPS(TTM)0.67
EY2.5%
EPS(NY)0.82
Fwd EY3.05%
FCF(TTM)1.29
FCFY4.81%
OCF(TTM)1.88
OCFY7.02%
SpS6.19
BVpS5.42
TBVpS4.76
PEG (NY)0.54
PEG (5Y)N/A
Graham Number9.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROCE | 9.69% | ||
| ROIC | 7.66% | ||
| ROICexc | 58.65% | ||
| ROICexgc | 479.54% | ||
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% | ||
| FCFM | 20.79% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 711.57% | ||
| Cap/Sales | 9.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 292.92% | ||
| Profit Quality | 83.36% | ||
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 | ||
| Altman-Z | 6.04 |
F-Score4
WACC8.78%
ROIC/WACC0.87
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y73.59%
EPS Next 2Y30.49%
EPS Next 3Y32.59%
EPS Next 5Y38.78%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year11.07%
Revenue Next 2Y11.24%
Revenue Next 3Y10.99%
Revenue Next 5Y10.04%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.82%
EBIT Next 3Y27.27%
EBIT Next 5Y43.9%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the ChartMill fundamental rating of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ACAD.
Can you provide the valuation status for ACADIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What is the earnings growth outlook for ACADIA PHARMACEUTICALS INC?
The Earnings per Share (EPS) of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 73.59% in the next year.